Concomitant high apoptosis inhibitor of macrophage (Aim) and low prostate-specific antigen (psa) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Concomitant high apoptosis inhibitor of macrophage (Aim) and low prostate-specific antigen (psa) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds